Status:
RECRUITING
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Lead Sponsor:
University Hospital, Brest
Conditions:
Polycythemia Vera
Essential Thrombocythemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Philadelphia-negative myeloproliferative neoplasms (MPN) are frequent and chronic myeloid malignancies including Polycythemia Vera (PV), essential thrombocythemia (ET), Primary Myelofibrosis (PMF) and...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
July 13 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 13 2027
Estimated Enrollment :
1308 Patients enrolled
Trial Details
Trial ID
NCT05198960
Start Date
July 13 2022
End Date
July 13 2027
Last Update
February 4 2025
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU d'Angers
Angers, France, 49933
2
CH d'Annecy
Annecy, France, 74374
3
CH d'Argenteuil
Argenteuil, France, 95100
4
CH d'Avignon
Avignon, France, 84000